BRAINTREE, Mass. and LACHEN, Switzerland, Oct. 3 /PRNewswire-FirstCall/ -- Haemonetics Corporation and Octapharma AG announced today the signing of a multi-year supply contract appointing Haemonetics' Swiss subsidiary as Octapharma's preferred provider of plasma collection technology in Europe. Under the agreement, Octapharma will use Haemonetics' technology to separate plasma from donor blood. Plasma is the source of numerous proteins used for drug development and therapeutic purposes. These proteins include albumin, clotting factors, and intravenous immunoglobulin (IVIG).
Octapharma, also a Swiss-based company, is an independent plasma fractionation specialist. One of the top five global plasma fractionators, Octapharma reported fiscal 2006 sales of euro 572 million with 32% growth year over year. The company owns four state-of-the-art fractionation facilities in Austria, France, Sweden, and Mexico, and operates a plant in Springe, Germany. Octapharma currently fractionates more than 2 million liters of plasma annually from both recovered and source plasma from the U.S. and Europe.
"In order to meet the increasing demand for Octapharma products, a key focus of the company is to extend production capacities in all our facilities," said Karl E. Clausen, Chief Financial Officer of Octapharma. "As part of this growth, we are pleased to be expanding our relationship with Haemonetics. Haemonetics delivers an excellent value proposition with plasma collection technologies, IT products, and services that can support the growth of Octapharma for years to come."
Stephen Swenson, General Manager of Global Plasma for Haemonetics, said, "Octapharma is a premier plasma collector and fractionator in Europe. We are delighted to be expanding our relationship."
As Haemonetics has been reporting, the plasma collection market
continues to be strong as collectors increase capacity to meet demand for
plasma-derived bio-pharmaceuticals. At the beginning of
|SOURCE Haemonetics Corporation|
Copyright©2007 PR Newswire.
All rights reserved